Dogwood Therapeutics Inc (DWTX)

Over the past six months, Dogwood Therapeutics' stock price has experienced significant volatility and underperformed the S&P500 Index. Key events include the report of Third Quarter 2025 Financial Results on November 6, 2025, and the announcement of the enrollment of the first 100 patients in its Halneuron® Phase 2b trial on November 11, 2025. On December 22, 2025, the company announced positive interim Phase 2b clinical trial results for Halneuron®, leading to a stock plunge. On January 12, 2026, the company announced a financing of up to $26.8 million. On January 15, 2026, Dogwood Therapeutics filed for an offering of up to 6,433,126 shares by selling stockholders. On February 2, 2026, Dogwood Therapeutics announced 50% enrollment in the ongoing Halneuron® Phase 2b trial. On March 18, 2026, Dogwood Therapeutics reported its Fourth Quarter and Full Year 2025 Financial Results, with a net loss of $35.5 million. On March 26, 2026, Dogwood Therapeutics highlighted pipeline progress and an extended cash runway.

As a development-stage biopharmaceutical company with a pre-revenue status, Dogwood Therapeutics, Inc. does not currently have commercialized products or services that would exhibit traditional demand seasonality. Its focus is on research and development, and therefore, demand seasonality for its products and services is not applicable at this stage.

Dogwood Therapeutics, Inc. (DWTX) is a development-stage biopharmaceutical company focused on creating new medicines for pain and neuropathy, operating within the Healthcare sector, specifically in Biotechnology and Drug Discovery. The company is dedicated to addressing unmet medical needs, including chemotherapy-induced neuropathic pain (CINP), peripheral neuropathy (CIPN), and fibromyalgia. Its pipeline includes Halneuron®, a non-opioid sodium channel blocker in Phase 2b development; SP16 IV, an LRP1 agonist; IMC-1, a combination of famciclovir and celecoxib; IMC-2, a combination of valacyclovir and celecoxib; and Serpin Peptide 16, in early Phase 1 development. The company, formerly known as Virios Therapeutics, Inc., changed its name in October 2024 and is currently focused on research and development.

Dogwood Therapeutics, Inc. is headquartered in Alpharetta, Georgia, United States. Its corporate office is located at 44 Milton Avenue, Alpharetta, GA 30009. Clinical trials, such as the HALT-CINP Phase 2b trial, are conducted at approximately 30 U.S. sites. Information regarding a broader international geographic footprint is not explicitly available.

Information specifically detailing Dogwood Therapeutics, Inc.'s brand reputation in the past year is not readily available. The company's public communications primarily focus on its scientific advancements, clinical development milestones, and financial performance.

Dogwood Therapeutics, Inc. has a mix of institutional and insider ownership. As of March 23, 2026, there are 12 institutional owners and shareholders holding a total of 70,190 shares, including Vanguard Group Inc and Geode Capital Management, Llc. Sealbond Ltd is the largest individual shareholder, owning 73.84% of the shares. Other significant individual and insider owners include William Pridgen, Richard Alan Burch, and Gregory Scott Duncan (CEO).